SkinBioTherapeutics plc (FRA:5KW)
Germany flag Germany · Delayed Price · Currency is EUR
0.2200
0.00 (0.00%)
At close: Jan 30, 2026

SkinBioTherapeutics Balance Sheet

Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash & Equivalents
4.780.81.311.84.61
Cash & Short-Term Investments
4.780.81.311.84.61
Cash Growth
496.75%-38.95%-27.32%-60.85%113.51%
Accounts Receivable
0.620.2800-
Other Receivables
0.790.060.30.330.21
Receivables
1.410.340.30.330.21
Inventory
0.80.470.030.12-
Prepaid Expenses
0.120.060.070.080.24
Total Current Assets
7.111.671.722.335.06
Property, Plant & Equipment
0.730.120.170.130.14
Goodwill
2.422.04---
Other Intangible Assets
1.871.390.70.630.53
Total Assets
12.135.222.593.085.73
Accounts Payable
0.510.280.190.070.08
Accrued Expenses
0.340.210.30.370.28
Short-Term Debt
-0.74---
Current Portion of Leases
0.110.040.030.030.03
Current Income Taxes Payable
0.030.03-0.030.02
Other Current Liabilities
0.470.500.010
Total Current Liabilities
1.471.80.530.510.4
Long-Term Debt
0.6----
Long-Term Leases
0.280.040.070.10.11
Long-Term Deferred Tax Liabilities
0.360.15---
Other Long-Term Liabilities
-0.25---
Total Liabilities
2.712.250.60.610.52
Common Stock
2.592.021.731.571.57
Additional Paid-In Capital
21.0914.5110.958.768.76
Retained Earnings
-14.7-14-11.12-8.29-5.5
Comprehensive Income & Other
0.440.440.440.440.38
Shareholders' Equity
9.422.971.992.485.22
Total Liabilities & Equity
12.135.222.593.085.73
Total Debt
0.990.820.10.130.14
Net Cash (Debt)
3.79-0.021.211.684.47
Net Cash Growth
---27.78%-62.48%107.04%
Net Cash Per Share
0.02-0.000.010.010.03
Filing Date Shares Outstanding
258.78202.26173.14156.78156.78
Total Common Shares Outstanding
258.78202.26173.14156.78156.78
Working Capital
5.64-0.131.191.824.66
Book Value Per Share
0.040.010.010.020.03
Tangible Book Value
5.13-0.461.291.854.69
Tangible Book Value Per Share
0.02-0.000.010.010.03
Source: S&P Global Market Intelligence. Standard template. Financial Sources.